Updated immunisation reference page: Needle phobia
We have recently updated our Needle phobia page to include the latest information and resources available for addressing needle phobia.
Our page includes information and strategies for health care providers, individuals and care givers to manage needle phobia and immunisation.
To view this page, please click on the following link:
SAEFVIC Rapid report: a new reporting pathway for COVID-19 vaccine AEFI
Reporting adverse events following immunisation (AEFI) is not mandatory in Victoria, however doing so allows the rapid investigation of any potential vaccine or system problems. This helps to ensure a safe and effective immunisation program and it maintains community confidence in vaccines.
The new SAEFVIC Rapid reporting pathway has been launched for reporting any common or expected side effects following a COVID-19 vaccine. Reporting via this pathway will not result in follow up of clinical symptoms however it will contribute to data collection and assist health authorities to understand the frequency of symptoms occurring. Should the vaccinee experience significant side effects, completing the SAEFVIC Extended report is recommended.
For more information on SAEFVIC, symptoms that should be reported, and instructions on how to report, please visit our immunisation reference page below:
MVEC: Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC)
Updated immunisation reference page: Vaccine confidence
We have recently updated our Vaccine confidence immunisation reference page to include the latest information and resources available to help address people’s questions and concerns about vaccines.
Our page includes information on how to talk to people who have concerns about vaccines, how to tackle misinformation and how to be a vaccine champion in your workplace or community.
To view this page, please click on the following link:
New immunisation reference page: Myocarditis and pericarditis following mRNA COVID-19 vaccines
Myocarditis is an inflammatory disease of the heart muscle, whilst pericarditis is an inflammatory disease of the lining of the heart muscle. They are rare conditions, most commonly associated with viral infections (including SARS-CoV-2) but can also be triggered by other factors such as medications and autoimmune conditions. Globally, an increased number of cases above an expected population rate of myocarditis and pericarditis have been reported in individuals who have received mRNA COVID-19 vaccines (eg. Comirnaty™ and Moderna).
Our new reference page discusses the temporal association of myocarditis and pericarditis with mRNA COVID-19 vaccination, symptoms, investigations, as well as the implications on future COVID-19 vaccination.
要阅读更多信息，请点击以下链接：
MVEC: Myocarditis and pericarditis following mRNA COVID-19 vaccines
New immunisation reference page: Moderna COVID-19 vaccine
Following the announcement by the Australian Government that 25 million doses (as well as additional variant specific versions) of Moderna's COVID-19 vaccine, Elasomeran, had been secured for the Australian population, this vaccine was last week granted provisional determination by the TGA.
Our new reference page explores the various clinical trials involving Elasomeran, as well as details the immunogenicity, efficacy and safety data available for this vaccine.
要阅读更多信息，请点击以下链接：
MVEC: Moderna COVID-19 vaccine
New immunisation reference page: COVID-19 mixed vaccine schedules
With the emergence of variant COVID-19 strains, global vaccine supply issues, and the need to rapidly immunise the population, a number of clinical trials are investigating the option of “mixed schedules”. Mixed schedules have been used previously in other vaccination strategies and involve the administration of different vaccine brands to complete a vaccine course.
Our new reference page explores the clinical trials underway which aim to determine the safety of mixed scheduling, the immunogenicity, as well as the recommendations for intervals between doses.
Due to a lack of available data, mixed vaccine schedules are not currently approved in Australia however are in use in Canada and across Europe.
要了解更多信息，请点击以下链接：
MVEC: COVID-19 mixed vaccine schedules
更新的免疫参考页：TTS、G6PD 和 COVID-19 疫苗和过敏
我们最近更新了一些免疫参考页面，以包含有关 COVID-19 疫苗的最新信息和建议。要查看这些页面，请点击以下链接：
微血管内皮细胞： 血栓形成伴血小板减少综合征 (TTS)
微血管内皮细胞： G6PD 缺乏症和疫苗
微血管内皮细胞： COVID-19 疫苗和过敏
新的免疫参考页面：COVID-19 疫苗接种：劳动力培训和应用流程
由于推出 COVID-19 疫苗需要进行大量免疫接种，因此需要扩大当前的免疫接种队伍。需要专门的培训和教育，以确保免疫接种人员得到适当的培训，以便安全有效地接种每种疫苗。
我们的新参考页面“COVID-19 疫苗接种：劳动力培训和申请流程”详细介绍了有关维多利亚州 COVID-19 免疫接种劳动力每位成员培训要求的常见问题。
要了解更多信息，请点击以下链接：
Raising Children Network - new COVID-19 vaccination: pregnancy and breastfeeding resource
MVEC 与 育儿网 to develop a new resource focused on providing COVID-19 vaccine recommendations for women who are pregnant, breastfeeding or planning pregnancy.
To view this article follow the link below:
COVID-19 vaccination: pregnancy and breastfeeding
Further information on vaccines for pregnant and breastfeeding women can be found via our immunisation reference pages below:
New immunisation reference page: COVID-19 vaccination in children
COVID-19 infections have generally produced more severe disease outcomes in adults and the older population, with children generally experiencing milder symptoms. For this reason, initial COVID-19 vaccine clinical trials and vaccine rollouts focused on the adult population. However, it is recognised that in order to achieve herd immunity within the community, the vaccination of children needs to be considered.
Our new reference page outlines the importance of conducting paediatric focused COVID-19 vaccine clinical trials and summarises the trials that are currently underway.
要阅读更多信息，请点击以下链接：
MVEC: COVID-19 vaccination in children